CA-NOMINAL
22.4.2024 19:29:30 CEST | Business Wire | Press release
Nominal, a company specializing in creating end-to-end data analysis solutions for industrial engineering teams, emerged from stealth to provide a faster, more reliable way to review test data and validate mission-critical systems. The startup raised $7.5M in Seed funding led by Lux Capital with support from Founders Fund and $20M in their Series A led by General Catalyst. Additional investors include Haystack VC, XYZ Ventures, Human Capital, Box Group, and Overmatch.
Nominal specializes in creating software solutions for the Aerospace, Defense, Industrial Machinery, Transportation, and Energy sectors with various partnerships across the U.S. government. The company is led by co-founder and CEO Cameron McCord, who has extensive experience in the private sector at prominent startups Anduril, Applied Intuition, and Saildrone and as a venture capitalist, and in the public sector as a veteran Nuclear Submarine Officer and Congressional Liaison for the Navy. McCord works closely with his co-founders Bryce Strauss, a former Lockheed Martin Space division systems engineer who worked on inter-planetary robotic missions and building software tools for engineers, and Jason Hoch, an experienced software engineer who has diverse experience creating data products for startups, Fortune 500 companies, and governments.
Nominal's platform is designed to handle sensitive government and industrial data. The company's leadership team brings over 15 years of combined experience in both hardware and software from organizations like SpaceX, Palantir, Anduril, Applied Intuition, NASA, Microsoft, and more.
“Building trust in industrial systems and the data that these systems generate is core to our mission at Nominal. As aerospace, defense, and industrial systems have rapidly become more complex and software-defined, the software tools and infrastructure that engineers and operators use to make sense of and validate these systems have lagged in a costly and dangerous way.” Cameron McCord, Co-founder and CEO of Nominal said, “We’re choosing now to come out of stealth because we feel ready to accelerate our mission to help engineers that develop, test, and validate mission-critical industrial systems. We are on an industrial software collision course. Time is ticking - for our commercial customers, this means getting a product safely to market faster, and for our government customers, it means fielding reliable and tested systems for any mission.”
With Nominal, teams can quickly test and deploy their complex hardware systems. Nominal is dedicated to providing a robust, end-to-end solution that simplifies workflows, fosters collaboration, and seamlessly scales with the evolving needs of its valued customers and partners. Nominal also enables teams and organizational-level collaboration and visibility to reflect the multidisciplinary and iterative nature of engineering. The more people in an engineering organization who can view a comprehensive data story, the better the understanding and insights gained.
"When we first met Nominal, what stood out to us was the intentionality by which Cameron, Bryce, and Jason are building the company. Nominal’s modern software suite is purpose-built for hardware engineers to manage the complex workflows of testing and developing high-stakes, breakthrough hardware systems. By hitting the industrial software collision course head-on, we believe Nominal can help unlock a renaissance of industrial innovation,” said Paul Kwan, Managing Partner, General Catalyst.
Nominal is utilizing this latest infusion of capital to uphold its commitment to delivering innovative solutions to the defense and aerospace sectors, including the rollout of its full-stack data analysis solution designed to facilitate and expedite the process of analyzing and reviewing test data for engineering teams. Beyond new product initiatives to meet growing customer demands, the company also intends to grow its teams and enhance its security and deployment capabilities.
About Nominal
Nominal is igniting the next industrial revolution. By allowing for rapid and accurate review of test data and the validation of critical systems through its comprehensive data analysis platform, Nominal provides modern workflows specifically tailored to the needs of engineering teams that develop, validate, and monitor hardware. At Nominal, we believe hardware engineers deserve the world’s best software. We are fully committed to helping our users more efficiently and effectively test and deploy mission-critical systems that will change the world. Nominal currently supports mission-critical data analysis and testing at companies across the aerospace, defense, energy, and industrial spheres including Varda Space, Muon Space, REGENT, Radiant Nuclear, the U.S. Air Force, and others. We are supported by leading venture investors such as General Catalyst, Lux Capital, Founders Fund, Haystack, XYZ Ventures, Human Capital, BoxGroup, and Overmatch. To learn more about Nominal and its innovative solutions, please visit nominal.io.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240418799842/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
